| Theme | Clinical Management of Esophageal Cancer 2017 -- Current Status and Issues | |
|---|---|---|
| Title | Salvage Photodynamic Therapy for Local Failure after Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma | |
| Publish Date | 2017/08 | |
| Author | Yusuke Amanuma | Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University |
| Author | Takahiro Horimatsu | Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University |
| Author | Manabu Muto | Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University |
| [ Summary ] | Photodynamic therapy (PDT) using talaporfin (Laserphyrin®) and a diode laser was approved in Japan in October 2015 to treat esophageal cancer after local failure of control by chemoradiotherapy (CRT)/radiotherapy (RT). PDT causes necrobiosis of cancer cells through a photochemical reaction. Four to 6 hours after administration of Laserphyrin, a diode laser is used to irradiate the lesion via a straight type fiber through an endoscope. The indications for salvage PDT are lesions limited to within the muscularis propria and not indicated for salvage endoscopic resection and surgery. In this trial, the local complete response rate was 88.5 %. There was no skin phototoxicity and no grade 3 or worse non‒hematological toxicities related to PDT. PDT using Laserphyrin and a diode laser is a safe and curative salvage treatment for local failure after CRT or RT for patients with esophageal cancer. | |